针对PI3K/AKT和MEK/ERK通路,以获得对改善外围糖尿病神经病变特征的协同效应
1Faculty of Biology and Environment, Ho Chi Minh City University of Industry and Trade, Ho Chi Minh City, Vietnam.
Journal of diabetes investigation
|August 20, 2024
概括
糖尿病神经病变治疗需要改进,不仅仅是血糖控制. 针对PI3K/AKT和MEK/ERK通路提供了神经再生和预防糖尿病神经病变变的有希望的策略.
科学领域:
- 神经科学是一个神经科学.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病神经病变影响30-50%的糖尿病患者,这给患者带来了重大的临床挑战.
- 目前的治疗主要集中在血糖管理上,导致不充分的临床结果.
- 对于解决神经退化和再生的新型治疗策略有着至关重要的需求.
研究的目的:
- 审查和讨论针对PI3K/AKT和MEK/ERK信号通路的潜力.
- 探索这些途径作为对外围糖尿病神经病变的更有效的治疗点.
- 重点关注神经再生和退行预防的双重方法的重要性.
主要方法:
- 关于糖尿病神经病变的现有文献的小型综述.
- 分析PI3K/AKT和MEK/ERK通路在周围神经健康中的作用.
- 讨论针对这些特定分子通路的治疗策略.
主要成果:
- PI3K/AKT和MEK/ERK通路是神经元生存和再生的关键调节者.
- 针对这些途径为增强糖尿病神经病变中神经修复提供了一个有希望的途径.
- 目前的治疗限制需要对这些分子标进行探索.
结论:
- 未来对外围糖尿病神经病变的治疗应包括针对PI3K/AKT和MEK/ERK通路的策略.
- 一个平衡的方法促进神经再生和预防退化是必不可少的.
- 这些途径提供了比目前的标准护理更有效的治疗方向.
更多相关视频
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
369
05:06Author Spotlight: Integrating Tai Chi with Mindfulness Training to Achieve an Effective Mind-Body Exercise
Published on: July 14, 2023
1.6K
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
Dipeptidyl Peptidase 4 Inhibitors
179
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
179
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
